

To
the Honourable
Mr. Gerasimos Voudouris
President of EOPYY

Cc.: Mr. An. Lykourantzou, Minister of Health
Mr. M. Salmas, Deputy Minister of Health
Mrs. Ch. Papanikolaou, Secretary General of Public Health
Mr. I. Tountas, President of EOF
Mrs. M. Skouroliaou, Vice-President of EOF
Mr. Bl. Sfyroeras, CEO of HDIKA

Chalandri, 4 October 2012

Expansion of e-prescribing by active substance

Dear Mr. Voudouris,

SFEE supports the extension of e-prescribing, nevertheless the following issues must be immediately solved:

- e-prescribing by active substance must be implemented only for the categories of medicines which include generics. For the time being, the reference price has been calculated for all the categories of medicines, regardless, whether they have generics or not, a fact that cause distortions:
 - Patients have to pay the difference even in cases of co-marketing where by mistake the medicines have a difference price. Several mistakes have not been corrected while the relevant petitions are pending
 - The reference price is calculated including even medicines which have been withdrawn, and patients are asked to pay the difference
- Medicines for diseases reimbursed 100% and medicines of law 3816/2010 must be excluded, since in this case there is no patient co-payment
- Non interchangeable medicines e.g narrow therapeutic margin, antipsychotics, biosimilars / biological medicines must be excluded. Narrow therapeutic margin medicines are protected in all EU countries since any change of the administered medicines leads to side effects which cost more for the system
- e-prescribing by active substance must be implemented only for the medicines included in the positive list and in the supplementary list


The e-prescribing system in force now includes and 32 medicines which have not been included in the positive or in the supplementary list (see annex).

It is possible that some medicines included in the positive or in the supplementary list are missing from the e-prescribing system.

Therefore, it is absolutely necessary to administer to pharmaceutical companies access code in the HDIKA e-prescribing system so as to ensure that the date included for the medicines of each company are correct.

In this context, we ask you to arrange a meeting so as to discuss the above issues.

Kind Regards,



Pascal Apostolides
Vice President



Fotis Maggalousis
Director General

FREE